RecruitingNCT04439708

Biomarkers and Choroidal Neovascularization

Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization


Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Enrollment

250 participants

Start Date

Jul 6, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria8

  • Patients of group 1:
  • Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
  • Patients without intravitreal injection or last intravitreal injection > 3 months
  • Informed signed consent
  • Patients of group 2:
  • Patients without choroidal neovascularization
  • Patients with intraocular surgery (cataract or vitrectomy surgery)
  • Signed consent

Exclusion Criteria8

  • Myocardial infarction < 12 months
  • Chronic renal failure
  • Inflammatory disease
  • Infectious disease :HIV, viral hepatitis, tuberculosis
  • Type 1 or 2 Diabetes
  • Patients treated by mineralocorticoid antagonist treatment.
  • Type 2 or 3 choroidal neovascularization
  • Pregnant woman

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood and aqueous humor biomarker of treatment response

Blood analyses and aqueous humor analysis


Locations(2)

Ophtalmopole Hôpital Cochin

Paris, France

Hôpital Foch

Suresnes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04439708


Related Trials